Core Viewpoint - 基石药业-B's stock price increased by over 3% in early trading, reflecting positive market sentiment following the announcement of its drug being included in the national medical insurance list [1] Group 1: Company Announcement - 基石药业-B announced that its drug, 普吉华® (Pralsetinib capsules, 100 mg), has been included in the latest version of the National Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List by China's National Healthcare Security Administration [1] - The new drug list will officially take effect on January 1, 2026 [1] - 基石药业 holds exclusive development and commercialization rights for 普吉华® in Greater China, which includes mainland China, Hong Kong, Macau, and Taiwan [1] Group 2: Partnership and Commercialization - 普吉华® was developed by Blueprint Medicines, which is set to be acquired by Sanofi in July 2025 [1] - In November 2023, 基石药业 granted exclusive commercialization rights for 普吉华® in mainland China to Shanghai Elios Pharmaceutical Technology Co., Ltd [1]
港股异动 | 基石药业-B(02616)早盘涨超3% 普拉替尼胶囊获纳入2025年国家医保目录